Wockhardt Limited (“Wockhardt”), a global pharmaceutical and biotechnology company, faced a significant dispute concerning the cancellation of its license to manufacture and distribute drugs in India. Majmudar & Partners provided strategic legal representation to Wockhardt, assisting in navigating the regulatory and judicial complexities of the case to protect its business interests.
Assistance with Dispute Resolution
Majmudar & Partners represented Wockhardt during this high-stakes regulatory dispute. Key contributions included:
- Regulatory Review and Legal Strategy Development: Conducted a detailed analysis of the regulatory grounds cited for the license cancellation. Developed a robust legal strategy to challenge the cancellation and safeguard Wockhardt’s manufacturing and distribution rights.
- Representation Before Authorities: Represented Wockhardt before the relevant drug regulatory authorities and appellate bodies, presenting arguments to demonstrate compliance with the applicable drug manufacturing and distribution regulations.
- Litigation Support: Provided litigation support, including drafting petitions and replies, to challenge the license cancellation in Indian courts.
- Ensuring Compliance: Advised Wockhardt on any immediate corrective measures required to address compliance issues, minimizing potential risks and ensuring adherence to Indian drug regulatory laws.
This dispute highlights the complex regulatory landscape faced by pharmaceutical companies in India. Through Majmudar & Partners’ expert guidance, Wockhardt was able to effectively contest the cancellation of its license, protecting its manufacturing and distribution rights and preserving its market position.
Majmudar & Partners has extensive experience in handling regulatory disputes and licensing challenges in the pharmaceutical sector. Contact us to explore how we can provide strategic legal solutions to protect your business interests in India.